Welcome to our dedicated page for Immatics N.V SEC filings (Ticker: IMTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immatics N.V. filings document a foreign private issuer whose regulatory record centers on clinical-stage oncology development, financing capacity and public-company governance. Form 6-K reports furnish press releases, interim reports and investor presentations covering PRAME cell therapy and TCR bispecific programs, including anzu-cel, IMA203CD8, IMA402 and IMA401 MAGEA4/8, along with financial results and business updates.
The filings also include incorporation-by-reference language for Form S-8 and Form F-3 registration statements, leadership and governance disclosures, forward-looking clinical and regulatory risk statements, and capital-structure or shareholder matters tied to the company's Nasdaq-traded security.
This Schedule 13G/A reports that Suvretta Capital Management, LLC and Aaron Cowen each have shared beneficial ownership of 12,030,129 ordinary shares of Immatics N.V., representing 9.9% of the class. Averill Master Fund, Ltd. reports shared beneficial ownership of 10,623,778 shares, representing 8.7% of the class. The filing shows no sole voting or sole dispositive power for any reporting person; all listed voting and dispositive power is shared. The filing states the securities are directly owned by advisory clients of Suvretta, and the reporting persons disclaim beneficial ownership except to the extent of pecuniary interest.
Immatics N.V. submitted a Form 6-K as a foreign private issuer to furnish materials related to its second quarter 2025 reporting. The company issued an interim report covering the three- and six-month period ended June 30, 2025, a press release with second quarter 2025 financial results and a business update, and an updated corporate investor presentation.
The interim report is attached as Exhibit 99.1, the press release as Exhibit 99.2, and the presentation as Exhibit 99.3. The interim report and the core portions of this Form 6-K (excluding the press release and presentation) are incorporated by reference into Immatics’ existing Form S-8 and Form F-3 registration statements, meaning those offering documents now formally include this updated interim information.
Wellington Management and related entities report beneficial ownership of 5,318,624 shares of Immatics N.V. common stock, representing approximately 4.38% of the class. The filing discloses no sole voting or dispositive power; voting is held as shared voting power of 4,545,848 shares and shared dispositive power of 5,318,624 shares. These shares are owned of record by clients of Wellington investment advisers.
The statement clarifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control; no client is identified as having the right to dividends or sale proceeds for more than 5% of the class.